anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The SARS-CoV-2 (COVID-19) pandemic has impacted the care of people living with HIV (PLWH). This study aims to characterize the impact of the pandemic on the length of HIV treatment gap lengths and viral loads among people living with HIV (PLWH) in British Columbia (BC), Canada, with a focus on Downtown Eastside (DTES), which is one of the most impoverished neighbourhoods in Canada. We analyzed data from the HIV/AIDS Drug Treatment Program from January 2019 to February 2022. The study had three phases: Pre-COVID, Early-COVID, and Late-COVID. We compared results for individuals residing in DTES, those not residing in DTES, and those with no fixed address. Treatment gap lengths and viral loads were analyzed using a zero-inflated negative binomial model and a two-part model, respectively, adjusting for demographic factors. Among the 8982 individuals, 93% were non-DTES residents, 6% were DTES residents, and 1% had no fixed address during each phase. DTES residents were more likely to be female, with Indigenous Ancestry, and have a history of injection drug use. Initially, the mean number of viral load measurements decreased for all PLWH during the Early-COVID, then remained constant. Treatment gap lengths increased for all three groups during Early-COVID. However, by Late-COVID, those with no fixed address approached pre-COVID levels, while the other two groups did not reach Early-COVID levels. Viral loads improved across each phase from Pre- to Early- to Late-COVID among people residing and not residing in DTES, while those with no fixed address experienced consistently worsening levels. Despite pandemic disruptions, both DTES and non-DTES areas enhanced HIV control, whereas individuals with no fixed address encountered challenges. This study offers insights into healthcare system preparedness for delivering HIV care during future pandemics, emphasizing community-driven interventions with a particular consideration of housing stability.
Plants are aerobic organisms that rely on molecular oxygen for respiratory energy production. Hypoxic conditions, with oxygen levels ranging between 1% and 5%, usually limit aerobic respiration and affect plant growth and development. Here, we demonstrate that the hypoxic microenvironment induced by active cell proliferation during the two-step plant regeneration process intrinsically represses the regeneration competence of the callus in Arabidopsis thaliana. We showed that hypoxia-repressed plant regeneration is mediated by the RELATED TO APETALA 2.12 (RAP2.12) protein, a member of the Ethylene Response Factor VII (ERF-VII) family. We found that the hypoxia-activated RAP2.12 protein promotes salicylic acid (SA) biosynthesis and defense responses, thereby inhibiting pluripotency acquisition and de novo shoot regeneration in calli. Molecular and genetic analyses revealed that RAP2.12 could bind directly to the SALICYLIC ACID INDUCTION DEFICIENT 2 (SID2) gene promoter and activate SA biosynthesis, repressing plant regeneration possibly via a PLETHORA (PLT)-dependent pathway. Consistently, the rap2.12 mutant calli exhibits enhanced shoot regeneration, which is impaired by SA treatment. Taken together, these findings uncover that the cell proliferation-dependent hypoxic microenvironment reduces cellular pluripotency and plant regeneration through the RAP2.12-SID2 module.
The invention belongs to the technical field of medicines, and particularly discloses a ginkgo leaf total flavone controlled-release tablet and a preparation method thereof. The controlled-release tablet disclosed by the invention is a tablet which is prepared by combining polyoxyethylene and a controlled-release skeleton material and adopting a conventional tablet preparation technology and has the zero-order release behavior characteristic. The controlled-release tablet consists of an active ingredient ginkgo leaf total flavone, a high polymer material polyoxyethylene (PEO), the controlled-release skeleton material and a certain amount of release rate conditioning agent. The active ingredients of the ginkgo leaf total flavone mainly comprise isorhamnetin, kaempferide and quercetin, and the total flavonoid glycoside content of the quercetin is not lower than 20%. Compared with a common tablet, the ginkgo leaf total flavone controlled-release tablet has the advantages that the controlled-release tablet can be used for maintaining the constancy of the blood concentration, reducing the adverse reactions of the medicines and improving the compliance of the patients. The preparation method is simple in technological operation, low in cost, easy to control and suitable for industrial large-scale production.
Coronary heart disease (CHD) remains the single largest killer of American men and women (45). Hyper¬triglyceridemia (elevated triglyceride \[TG\] concentration in the blood) has been shown to be a significant independent risk factor for CHD (7;8;25), accordingly, treatment for hypertriglyceridemia has been included in the Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program (36). In a meta-analysis of 21 population-based prospective studies including a total of 65,863 men and 11,089 women, each increase of 89 mg/dl (1 mmol/l) in TG concentration was associated with a 32% increase in CHD risk in men and 76% increase in women (3). Thus, hypertriglyceridemia is an even stronger risk factor for CHD in women than in men.

The prevalence of hypertriglyceridemia is high. It is a common finding with aging, and is also associated with overweight, obesity, diabetes, and renal disease (39). With the aging of the US population and ongoing epidemics of obesity and type 2-diabetes, the number of individuals with conditions associated with elevated TG levels is likely to grow.

4.1.2 Effect of Amino Acids on Plasma Triglyceride Concentration In an effort to clarify the potential independent effect of protein on plasma and tissue lipids, we supplemented a normal weight-maintaining diet with a relatively small amount of amino acids (\~90 kcal/day) between meals. We measured tissue lipids in addition to plasma lipids since the increase in insulin resistance with aging has been linked to increased fat accumulation in muscle and liver tissue (20;63). Also, it has repeatedly been shown that amino acid intake stimulates muscle protein synthesis and improves muscle protein net balance (86). Our hypothesis was that supplementation of the normal diet with a mixture of amino acids will reduce circulating and tissue TG concentrations and improve insulin sensitivity in elderly subjects with impaired glucose tolerance. Twelve impaired glucose tolerant elderly ingested 11 g of essential amino acids (EAA) + arginine twice a day for 16 weeks, after a 7 week control run in. Diet and activity were not otherwise modified. We found individuals consuming the EAA supplement had improved physical function. Further, these individuals had lower plasma and liver TG concentrations than before supplementation, and total cholesterol and VLDL-cholesterol concentrations were also lower after supplementations (12). In the present study, we will investigate this by supplementing the diet of older subjects shown to have hypertriglyceridemia.
Patients with chronic hepatitis C treated with direct acting antivirals (DAAs), collect basic data before antiviral therapy, and during the period of PR antiviral treatment, January, March, June, September, December Follow-up was performed every 3-6 months during January, March, and withdrawal follow-up during DAAs antiviral therapy. Clinical biochemistry, HCV RNA and serological markers (anti-HCV), AFP, and liver imaging were performed at follow-up. Liver ultrasound) check.
Prenatal ethanol exposure can cause a broad range of abnormalities in newborns known as Fetal Alcohol Spectrum Disorder (FASD). Despite significant progress in understanding the disease mechanisms of FASD, there remains a strong global need for effective therapies. To evaluate the therapeutic potential of sulforaphane (SFN), an active compound extracted from cruciferous vegetables, in preventing FASD, ethanol-exposed zebrafish embryos were pretreated, co-treated, or post-treated with various concentrations of SFN. The FASD-like morphological features, survival rate, hatching rate, and vascular development were then assessed in the zebrafish embryos. It was found that pretreatment with 2 μM SFN during 3-24 hpf had no noticeable protective effects against teratogenicity induced by subsequent 1.5% ethanol exposure during 24-48 hpf. In contrast, co-treatment with 2 μM SFN and 1.5% ethanol during 3-24 hpf significantly alleviated a range of ethanol-induced malformations, including reduced body length, small eyes, reduced brain size, small otic vesicle, small jaw, and pericardial edema. Post-treatment with 3 μM SFN for 4 days following 1.5% ethanol exposure during 3-24 hpf also significantly reduced the characteristic features of FASD, decreasing the mortality rate and restoring body length, eye size, brain size, and otic vesicle circumference. Moreover, we found that ethanol, even at a low dose (0.5%), causes vascular development deficit in the zebrafish embryos, which were also largely rescued by SFN treatment. These data indicated that SFN has great potential to be used in the prevention and treatment of FASD.
Immunostimulatory sequence-specific RNA oligonucleotides corresponding to 3' terminal sequences of single-stranded minus-sense RNA genomic RNAs are provided. Also provided are compositions and methods relating to an immunostimulatory 4-mer RNA motif provided as 5'-C/U-U-G/U-U-3'. Incorporation of this short RNA motif is sufficient to confer new and altered immunostimulatory properties in new and existing oligonucleotides, including CpG oligodeoxynucleotides. Also provided are methods for use of the immunostimulatory RNA oligonucleotides and DNA:RNA chimeric oligonucleotides of the invention to induce an immune response in vitro and in vivo, as well as to treat allergy, asthma, infection, and cancer in a subject. Single-stranded oligoribonucleotides of the invention are believed to signal through a Toll-like receptor (TLR) chosen from TLR9, TLR8, TLR7, and TLR3. The oligoribonucleotides can also be used in a method to screen for TLR antagonists.
Exploring highly sensitive flexible electronic skins (e-skins) that can mimic the tactile and pain perception of human skin is an important prerequisite for achieving biomimetic robots and intelligent prosthetics. However, it is still difficult to realize both touch and pain sensing using a single pressure sensor. Herein, a novel flexible capacitive pressure sensor that can distinguish noxious pressure stimuli is proposed for detecting touch and pain, which is composed of a porous polydimethylsiloxane (PDMS) skeleton and a sodium alginate (SA) hydrogel core. The sensor employs two different working mechanisms depending on the range of external pressure, determining the mechanism of operation for transducing the sense of touch or pain. Such a unique structural design plays a crucial role in enhancing pain perception, leading to maximum sensitivity (14.25 kPa-1) in a large pressure regime (up to 400 kPa) and an adjustable pressure threshold. Moreover, the sensor also exhibits a fast response (45 ms) and recovery speed (70 ms), ensuring a sufficiently fast response to noxious pressure stimuli. Finally, we demonstrate the capabilities of a robotic hand based on the pressure sensor for precisely detecting both touch and pain, which shows great promise in developing intelligent robots and prosthetic limbs to prevent possible damage under external noxious stimuli.
OBJECTIVE: The only commercially available thoracic branched endoprosthesis (TBE) for treatment of the aortic arch was released in 2022. Limited data outside of clinical trial results have been reported. This study describes the demographics, anatomic details, and outcomes for patients treated for zone 0 to 2 using TBEs outside of a clinical trial.
METHODS: All patients treated using TBEs for zone 0 to 2 were included. Patients treated as part of the clinical trial for zone 0 to 1 (n = 6) were excluded. Patient demographics, comorbidities, anatomic and operative details, and outcomes were reported. Outcomes and survival were then compared between groups.
RESULTS: Of 40 patients, six patients underwent repair of zone 0, three of zone 1, and 31 of zone 2. There were no differences in demographics, comorbidities, or operative details by zone of treatment; however, the frequency of genetic aortopathy differed (zone 0: 0%; zone 1: 67%; and zone 2: 6.4%; P < .01). Seventy-three percent of patients were treated for dissection vs 27% with isolated aneurysms. Of the patients, 2.5% were treated for rupture, 22% were treated for symptomatic aneurysms, and 75% were treated electively. Forty-eight percent of repairs included a proximal cuff, and 83% received distal extension. Technical success was achieved in 100% of patients. Mean fluoroscopy time was 18 minutes, and median fluoroscopy dose was 416 mGy. Sixty percent of patients had prior aortic ascending/arch repair. TBE was planned as part of a complete thoracoabdominal repair in 45% of patients. Thirty-day mortality was 2.5% overall, with a single death in a zone 0 patient that occurred at day 1 due to a myocardial infarction. There were no reinterventions within 30 days. All other outcomes were similar. The 30-day stroke rate was 5.0%. The strokes occurred at day 6 (zone 1) and day 15 (zone 2); however, both were due to occlusion of a prior proximal surgical bypass and unrelated to the TBE side branch or embolization. Specifically, both patients had occlusion of a branch of their prior zone 1 or zone 2 arch replacement. An endoleak occurred in 7.5% of patients at 30-day follow-up (type II: 5.0%; unknown: 2.5%). At a mean follow-up of 6.6 months, 100% of side branches were patent.
CONCLUSIONS: Repair of the aortic arch including TBE can be performed electively and urgently with acceptable stroke and death rates. TBE provides a valuable tool for patients requiring complete repair of a thoracoabdominal aneurysm. Continued investigation is underway to assess long-term safety and efficacy outside of the clinical trial.
Provided are DNA sequences encoding cell cycle interacting proteins as well as methods for obtaining the same. Furthermore, vectors comprising said DNA  sequences are described, wherein the DNA sequences preferably are operatively linked to regulatory elements allowing expression in prokaryotic and/or eukaryotic host cells. In addition, proteins encoded by said DNA sequences, antibodies to said proteins and methods for their production are provided.  Also described is a method for controlling or altering growth characteristics of a plant and/or a plant cell comprising introduction and/or expression of one or more cell cycle regulatory proteins functional in a plant or parts thereof and/or one or more DNA sequences encoding such proteins. Also provided are regulatory sequences controling the expression of the above described cell cycle interacting proteins. Method for the identification of compounds being capable of activating or inhibiting the cell cycle are described as well.  Furhter described are diagnostic compositions comprising the aforementioned DNA sequences, regulatory sequences, proteins, antibodies, inhibitors and activators. Furthermore, transgenic plant cells, plant tissue and plants containing the above-described DNA sequences and vectors are described as well as the use of the aforementioned DNA sequences, vectors, proteins, regulatory sequences, antibodies and/or compounds identified by the method of the invention in plant cell and tissue culture, plant breeding and/or agriculture.
A pure traditional Chinese medicine preparation for treating deep burn is prepared from the following raw materials in parts by weight: the raw materials are prepared according to the following gram weight ratio: 15g of madder, 15g of motherwort, 15g of desmodium, 10g of creeping euphorbia, 10g of dragon's blood, 12g of earthworm, 10g of angelica, 10g of white peony root, 10g of tuckahoe, 10g of radix salviae miltiorrhizae, 20g of salvia miltiorrhiza, 10g of rhubarb, 10g of white mulberry root-bark, 10g of rhizoma bletillae, 12g of turmeric, 20g of rhizoma alismatis, 20g of trichosanthes root, 10g of cowherb seed, 20g of astragalus, 10g of mustard seed, 20g of pangolin and 10g of cicada slough. Selecting, removing non-medicinal impurities, adding sanguis Draxonis, soaking in 40% Chinese liquor as solvent for half a year, and spraying the medicinal liquid on the affected part. The medicine residues are dried in the sun and mixed with the dragon's blood by machining 200-mesh powder, and the dry-wet comprehensive therapy of powder and spray is specially used for external application on the wound surface. The medicine has multiple functions, and the detumescence effect is 3 times of that of other treatments. Can inhibit exudation within 24 hr, and the treatment course is shortened by 15-60 days. The invention is a Chinese medicinal preparation, has excellent curative effect on deep burn, electric injury, trauma, frostbite, bedsore and herpes zoster, has the cure rate of about 95 percent, does not plant skin, cause disability, leave scars, does not influence physiological function, does not suffer from complications such as septicemia and the like.
The invention provides neural crest cells applicable to regenerative medicine in a treatment of a nervous system disease, disorder or state by a simple method. In particular, the invention provides fat-derived neural crest cells. The invention also provides neural crest cells induced from fat-derived stem cells. The invention also provides a method for preparing the neural crest cells. The method includes the steps of: A) obtaining progenitor cells from fat; and B) subjecting the stem cells to conditions to induce neural crest cells. The invention also provides a composition and a mixture for cell transplantation containing the neural crest cells, a method for cell transplantation and use of the neural crest cells for preparing a pharmaceutical.
The invention discloses a phosphorus oxide indole derivative, a preparation method and chemical and biological application thereof. The phosphorus oxide indole derivative is characterized in that phosphorus oxide is taken as a basic acceptor structural unit, triphenylamine is connected to alpha or beta sites of a phosphorus-containing five-membered ring to be taken as a donor unit, and pyridine is connected to the rest beta or alpha sites to be taken as an alkylation salifying unit. The compounds can be applied to the field of chemical biology. The phosphorus oxide indole derivative provided by the invention can be applied to the preparation of medicines for photodynamic therapy of tumors or tumor cells. The phosphorus oxide indole derivative provided by the invention can be applied to cell imaging and dead cell specific marking. The phosphorus oxide indole derivative provided by the invention can be applied to microbial imaging and antimicrobial adhesion. The compound has the characteristics of good chemical stability, thermal stability, photobleaching resistance, biocompatibility, large Stokes shift, high aggregative state fluorescence quantum yield and high imaging signal-to-noise ratio.
Group randomly receiving desonide cream as the treatment cream for 3 weeks. Fifteen (15) gram tubes are dispensed at the beginning of each week and will be applied twice daily, by the subject, during the 3 week treatment phase.
BACKGROUND: We investigated the individual and interaction effects of maternal plasma 𝛂- and ϒ-tocopherol levels (vitamin E isomers) on child asthma and wheeze at age 8-9.
METHODS: Mother-child dyads were enrolled between 2006 and 2011 into the Conditions Affecting Neurocognitive Development and Learning in Early Childhood (CANDLE) prenatal cohort. Maternal second-trimester samples were analyzed for tocopherol and lipid concentrations. We assessed child asthma/wheeze using the International Study of Asthma and Allergies in Childhood (ISAAC) and other self-reported Ent wheeze. In multivariable logistic regression analyses, we assessed associations between vitamin E isomers and child asthma/wheeze outcomes (n = 847 mother-child dyads) and tested for prespecified interaction terms.
RESULTS: Median cholesterol-corrected tocopherol levels (interquartile range (IQR)) were 5.0 (4.3-5.7) and 0.8 (0.7-0.9) (umol/mmol) for 𝛂- and ϒ-tocopherol, respectively. Associations between 𝛂-tocopherol and asthma outcome variables were inverse but not statistically significant. In contrast, for ϒ-tocopherol, associations were in the positive direction, but also nonsignificant. Interactions analysis between tocopherols did not reach statistical significance for any outcome. Among children of women with a history of asthma, the likelihood of ever asthma in the child appears to be decreasing with increasing maternal 𝛂-tocopherol levels, whereas this trend was not observed among those without a history of asthma (p-interaction = .05).
CONCLUSION: We observed no associations for prenatal 𝛂- or ϒ-tocopherol concentrations with child asthma/wheeze. We detected some evidence of effect modification by maternal asthma history in associations between 𝛂-tocopherol and child asthma.
A medical facility structure that allows a patient to navigate their way through the facility in a straightforward manner. The medical facility includes a long main corridor that extends from an entrance to an exit of the medical facility. The medical facility also includes at least two short dead-end hallways that extend perpendicularly from the main corridor. Each room within the medical facility is provided with a unique room number, with room numbers being provided in sequential order based on a distance of each room from the entrance. When a patient goes to the facility for treatment, the patient first goes to a counter located nearby the entrance, and it is determined if a facility staff member is currently available to treat the patient, If so, the patient is told to go to a particular room number, which can be accessed either directly from the main corridor or from one of the short dead-end hallways. Signs are provided on the main corridor to indicate which rooms are located in each of the hallways, to allow the patient to easily find their way to the proper room.
The study is a prospective, multi-center, single arm cohort study of omission of adjuvant whole breast radiation therapy (WBRT) following breast conserving surgery (BCS) in patients with a pathological complete response (pCR) following neoadjuvant chemotherapy (NAC). Eligible and consenting female patients with newly diagnosed T1-3 node negative breast cancer with no clinical evidence of distant metastatic disease, who have been treated with NAC, BCS and axillary staging surgery with final pathology demonstrating a pCR (ypT0N0) will be enrolled to the study and followed. The first analysis is planned when follow-up is a median of 5 years. Study participants will not receive adjuvant WBRT, the current standard of care.

The primary outcome is ipsilateral breast tumour recurrence (IBTR) at median 5-year follow-up. Study participants will be followed and assessed for local recurrence, regional recurrence, distant recurrence, DFS and OS. In addition, any additional breast cancer treatments received by the participant for the first recurrence event including repeat BCS, mastectomy, additional systemic therapy and radiation therapy (RT) will be documented. The planned sample size is 352 study participants.
A traditional phase I dose escalation design is proposed to assess the feasibility and tolerability of romidepsin in combination with GDP, where treatment will be escalated. Treatment will be given for 6 cycles unless there is evidence of progression prior to completion of the 6 cycles or tolerability to the regimen is not sustained.